カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の神経芽腫に対する化学療法薬市場2023年：企業・地域・タイプ・用途別分析

■ 英語タイトル：Global Chemotherapy Drugs for Neuroblastoma Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR23SM7817）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR23SM7817
■ 発行日：2023年9月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：103
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥501,120見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥751,680見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,002,240見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の神経芽腫に対する化学療法薬市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

GlobalInfoResearchの最新の調査によると、世界の神経芽腫に対する化学療法薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の神経芽腫に対する化学療法薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 神経芽腫に対する化学療法薬の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

神経芽腫に対する化学療法薬市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・シクロホスファミド、シスプラチンまたはカルボプラチン、ビンクリスチン、ドキソルビシン（アドリアマイシン）、エトポシド、その他

用途別セグメント
・病院、診療所、その他

主要な市場プレーヤー
・Baxter Healthcare、Ingenus Pharmaceuticals、ANI Pharmaceuticals、Teva Pharmaceuticals、Qilu Pharmaceutical、Pfizer、Hikma Pharmaceuticals、Fresenius Kabi、Accord Healthcare、Viatris

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、神経芽腫に対する化学療法薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な神経芽腫に対する化学療法薬メーカーの企業概要、2019年～2022年までの神経芽腫に対する化学療法薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な神経芽腫に対する化学療法薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別神経芽腫に対する化学療法薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの神経芽腫に対する化学療法薬のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での神経芽腫に対する化学療法薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および神経芽腫に対する化学療法薬の産業チェーンを掲載しています。
・第14、15章では、神経芽腫に対する化学療法薬の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 神経芽腫に対する化学療法薬の概要
– タイプ別分析（2018年vs2022年vs2029年）：シクロホスファミド、シスプラチンまたはカルボプラチン、ビンクリスチン、ドキソルビシン（アドリアマイシン）、エトポシド、その他
– 用途別分析（2018年vs2022年vs2029年）：病院、診療所、その他
– 世界の神経芽腫に対する化学療法薬市場規模・予測
– 世界の神経芽腫に対する化学療法薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Baxter Healthcare、Ingenus Pharmaceuticals、ANI Pharmaceuticals、Teva Pharmaceuticals、Qilu Pharmaceutical、Pfizer、Hikma Pharmaceuticals、Fresenius Kabi、Accord Healthcare、Viatris
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：シクロホスファミド、シスプラチンまたはカルボプラチン、ビンクリスチン、ドキソルビシン（アドリアマイシン）、エトポシド、その他
・用途別分析2018年-2029年：病院、診療所、その他
・神経芽腫に対する化学療法薬の北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・神経芽腫に対する化学療法薬のヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・神経芽腫に対する化学療法薬のアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・神経芽腫に対する化学療法薬の南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・神経芽腫に対する化学療法薬の中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Product Overview and Scope of Chemotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Cyclophosphamide
1.3.3 Cisplatin or Carboplatin
1.3.4 Vincristine
1.3.5 Doxorubicin (Adriamycin)
1.3.6 Etoposide
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Chemotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Chemotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Baxter Healthcare
2.1.1 Baxter Healthcare Details
2.1.2 Baxter Healthcare Major Business
2.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
2.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Baxter Healthcare Recent Developments/Updates
2.2 Ingenus Pharmaceuticals
2.2.1 Ingenus Pharmaceuticals Details
2.2.2 Ingenus Pharmaceuticals Major Business
2.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.3 ANI Pharmaceuticals
2.3.1 ANI Pharmaceuticals Details
2.3.2 ANI Pharmaceuticals Major Business
2.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 ANI Pharmaceuticals Recent Developments/Updates
2.4 Teva Pharmaceuticals
2.4.1 Teva Pharmaceuticals Details
2.4.2 Teva Pharmaceuticals Major Business
2.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Teva Pharmaceuticals Recent Developments/Updates
2.5 Qilu Pharmaceutical
2.5.1 Qilu Pharmaceutical Details
2.5.2 Qilu Pharmaceutical Major Business
2.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Qilu Pharmaceutical Recent Developments/Updates
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments/Updates
2.7 Hikma Pharmaceuticals
2.7.1 Hikma Pharmaceuticals Details
2.7.2 Hikma Pharmaceuticals Major Business
2.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
2.8 Fresenius Kabi
2.8.1 Fresenius Kabi Details
2.8.2 Fresenius Kabi Major Business
2.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Fresenius Kabi Recent Developments/Updates
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Accord Healthcare Recent Developments/Updates
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
2.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Viatris Recent Developments/Updates
3 Competitive Environment: Chemotherapy Drugs for Neuroblastoma by Manufacturer
3.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Chemotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Chemotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Chemotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 North America
7.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Chemotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Chemotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Chemotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Chemotherapy Drugs for Neuroblastoma Market Drivers
12.2 Chemotherapy Drugs for Neuroblastoma Market Restraints
12.3 Chemotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Chemotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Chemotherapy Drugs for Neuroblastoma
13.3 Chemotherapy Drugs for Neuroblastoma Production Process
13.4 Chemotherapy Drugs for Neuroblastoma Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Chemotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Chemotherapy Drugs for Neuroblastoma Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 4. Baxter Healthcare Major Business
Table 5. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 6. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Baxter Healthcare Recent Developments/Updates
Table 8. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Ingenus Pharmaceuticals Major Business
Table 10. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 11. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Ingenus Pharmaceuticals Recent Developments/Updates
Table 13. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. ANI Pharmaceuticals Major Business
Table 15. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 16. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. ANI Pharmaceuticals Recent Developments/Updates
Table 18. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. Teva Pharmaceuticals Major Business
Table 20. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 21. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Teva Pharmaceuticals Recent Developments/Updates
Table 23. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 24. Qilu Pharmaceutical Major Business
Table 25. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
Table 26. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Qilu Pharmaceutical Recent Developments/Updates
Table 28. Pfizer Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer Major Business
Table 30. Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
Table 31. Pfizer Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer Recent Developments/Updates
Table 33. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Hikma Pharmaceuticals Major Business
Table 35. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 36. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Hikma Pharmaceuticals Recent Developments/Updates
Table 38. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 39. Fresenius Kabi Major Business
Table 40. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
Table 41. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Fresenius Kabi Recent Developments/Updates
Table 43. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 44. Accord Healthcare Major Business
Table 45. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 46. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Accord Healthcare Recent Developments/Updates
Table 48. Viatris Basic Information, Manufacturing Base and Competitors
Table 49. Viatris Major Business
Table 50. Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
Table 51. Viatris Chemotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Viatris Recent Developments/Updates
Table 53. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Chemotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Chemotherapy Drugs for Neuroblastoma, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Chemotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 58. Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 59. Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 60. Chemotherapy Drugs for Neuroblastoma New Market Entrants and Barriers to Market Entry
Table 61. Chemotherapy Drugs for Neuroblastoma Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Chemotherapy Drugs for Neuroblastoma Raw Material
Table 121. Key Manufacturers of Chemotherapy Drugs for Neuroblastoma Raw Materials
Table 122. Chemotherapy Drugs for Neuroblastoma Typical Distributors
Table 123. Chemotherapy Drugs for Neuroblastoma Typical Customers
List of Figures
Figure 1. Chemotherapy Drugs for Neuroblastoma Picture
Figure 2. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type in 2022
Figure 4. Cyclophosphamide Examples
Figure 5. Cisplatin or Carboplatin Examples
Figure 6. Vincristine Examples
Figure 7. Doxorubicin (Adriamycin) Examples
Figure 8. Etoposide Examples
Figure 9. Other Examples
Figure 10. Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 11. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application in 2022
Figure 12. Hospital Examples
Figure 13. Clinic Examples
Figure 14. Other Examples
Figure 15. Global Chemotherapy Drugs for Neuroblastoma Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Chemotherapy Drugs for Neuroblastoma Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029) & (K Units)
Figure 18. Global Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 19. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Manufacturer in 2022
Figure 20. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Manufacturer in 2022
Figure 21. Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 22. Top 3 Chemotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Top 6 Chemotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 25. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 26. North America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 27. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 28. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 29. South America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 30. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 31. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 32. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type (2018-2029)
Figure 33. Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 34. Global Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 35. Global Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application (2018-2029)
Figure 36. Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 37. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 38. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 39. North America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 40. North America Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 41. United States Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Canada Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Mexico Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 45. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 46. Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 47. Europe Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 48. Germany Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. France Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. United Kingdom Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Russia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Italy Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 54. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 55. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 56. Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 57. China Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Japan Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Korea Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. India Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Southeast Asia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Australia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 64. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 65. South America Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 66. South America Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 67. Brazil Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Argentina Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 70. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 71. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 72. Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 73. Turkey Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Egypt Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Saudi Arabia Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. South Africa Chemotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Chemotherapy Drugs for Neuroblastoma Market Drivers
Figure 78. Chemotherapy Drugs for Neuroblastoma Market Restraints
Figure 79. Chemotherapy Drugs for Neuroblastoma Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Chemotherapy Drugs for Neuroblastoma in 2022
Figure 82. Manufacturing Process Analysis of Chemotherapy Drugs for Neuroblastoma
Figure 83. Chemotherapy Drugs for Neuroblastoma Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source

※参考情報

神経芽腫は小児において最も一般的な固形腫瘍の一つであり、主に神経系の組織から発生します。通常、神経芽腫は副腎や交感神経系に起こります。この腫瘍は、特に幼児や小児に多く見られ、早期に発見して適切に治療を行うことが非常に重要です。その治療方法の一つが化学療法です。

化学療法は、がん細胞を攻撃し、その成長を抑えるために化学薬品を用いる治療法です。神経芽腫に対する化学療法薬は、主に腫瘍を縮小するために使用されることが多く、単独で使用されることもあれば、手術や放射線療法と併用されることもあります。化学療法の目的は、腫瘍を効果的に縮小させ、手術やその他の治療法の成功を高めることにあります。

神経芽腫に用いられる化学療法薬は、数種類の異なるクラスに分けられます。一般的に使用される薬剤には、アルキル化剤、抗代謝薬、植物アルカロイド、そして抗生物質系の薬剤が含まれます。アルキル化剤は、がん細胞のDNAに結合してその複製を妨げることによって効果を発揮します。代表的なものにはシクロフォスファミドやイホスファミドがあります。これらの薬剤は、腫瘍細胞の分裂を減少させる働きを持っています。

抗代謝薬は、正常な細胞とがん細胞の代謝過程を阻害することで作用します。メトトレキサートやフルオロウラシルなどがその例にあたります。これらの薬剤は、がん細胞が必要とする栄養素の供給を制限することにより、腫瘍の増殖を抑えることができます。

植物アルカロイドに属する薬剤は、細胞周期に特有の作用を持つものが多いです。バィンクリスチンやタキソールなどが代表的です。これらの薬は、細胞分裂の過程を妨げることによってがん細胞を排除するのに役立ちます。さらに、抗生物質系の薬剤も使用されることがありますが、これは主に細胞のDNAに影響を与え、細胞死を引き起こすことによって効果を発揮します。ドキソルビシンがその一例です。

神経芽腫における化学療法は、腫瘍のステージと患者の年齢に応じて用い方が変わります。小さな腫瘍や低リスクのケースでは、化学療法は使わないこともありますが、進行した腫瘍や高リスクのケースでは、積極的に化学療法を用いて病気を抑制します。特に切除が難しい場合や、再発・転移のリスクが高い際には、化学療法が重要な治療手段となります。

化学療法の治療効果を高めるためには、最近では生物学的治療法や免疫療法と併用するアプローチも模索されています。これにより、化学療法の効果を補強し、副作用を軽減することが期待されています。また、腫瘍に対する個別化医療の考え方も進んでおり、患者一人一人に最適な治療法を提供するための研究が続けられています。

ただし、化学療法は非常に効果的ではありますが、副作用が存在することも忘れてはなりません。代表的な副作用には、吐き気、脱毛、感染症のリスク上昇、貧血、血小板数の減少などがあります。これらの副作用は時に治療の継続を困難にすることがあるため、医療チームは副作用の管理にも注力しています。

患者の生活の質を向上させるためには、化学療法による治療だけでなく、支持療法や心理的サポートも重要です。化学療法中は、身体的なケアだけでなく、感情的、社会的なケアも必要となるため、医療チームが協力し、包括的な治療プランを提供することが求められます。

神経芽腫に対する化学療法は、今後も新しい研究や技術の進展によって、より安全で効果的な治療法が開発され続けることでしょう。新たな薬剤の開発や、既存の治療法の改良が進むことで、患者に対する治療結果や生存率を向上させることが期待されています。神経芽腫の患者に対する理解が深まること、そしてそれに基づいた支援体制が構築されることが重要です。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の化学療法用コールドハット市場2023年：企業・地域・タイプ・用途別分析
  • 世界のNSAID点眼薬市場2023年：企業・地域・タイプ・用途別分析
  • 世界のGLP-1RA医薬品市場2023年：企業・地域・タイプ・用途別分析
  • 世界の眼科用非ステロイド性抗炎症薬市場2023年：企業・地域・タイプ・用途別分析
  • 世界の心筋梗塞治療薬市場2023年：企業・地域・タイプ・用途別分析
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR23SM7817 )"世界の神経芽腫に対する化学療法薬市場2023年：企業・地域・タイプ・用途別分析" (英文：Global Chemotherapy Drugs for Neuroblastoma Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。